Free Newsletter
Biotech co. defends gene therapy trial standards
The death of Jolee Mohr in a gene therapy trial undertaken by Seattle-based Targeted Genetics has once again thrown a spotlight on the safety record of the whole gene therapy field. The family wants to know why she was recruited for a study that offered her next to no chance of a medical benefit. The 15-page consent agreement is also being scrutinized, as the company insists that it did nothing improper in pursuing testing of tgAAC94, which uses a specially engineered virus to transport a gene. When working properly, the therapy produces proteins that eliminate the inflammatory molecules that cause arthritis. But now questions are being raised about breaches in the consent process as the family finds out that the consent agreement was signed on first sight--rather than studied--and that the principal investigator suggested she volunteer rather than having someone else make the proposal. It all represents another huge setback for gene therapy, which has been periodically roiled over the years by the unexpected deaths of trial participants.
- here's the report from The Washington Post
Related Articles:
Trial death spurs questions about gene therapy. Report
Targeted Genetics study on hold. Report
Gene therapy makes a big comeback. Report
New advances made in gene therapy for HIV. Report
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Comments (1) | Post a comment